Case Reports Open access

COVID-19 as potential aggravating factor for the natural course of new onset-dermatomyositis

Authors

Published
3 May 2022
Section
Case Reports
DOI
10.4081/reumatismo.2022.1440

Abstract

Borges et al. have recently reported the first case of a dermatomyositis onset in close association with established coronavirus disease 2019 (COVID-19). Similarly, we report a patient who, on the contrary, had COVID-19 following early established dermatomyositis. We report prospectively the outcome of her disease.

Keywords

References

  1. Lundberg I, Tjärnlund A, Bottai M, et al. 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Arthritis Rheumatol. 2017; 76: 2271-82. DOI: https://doi.org/10.1002/art.40320
  2. Borges NH, Godoy TM, Kahlo BS. Insorgenza di dermatomiosite in stretta associazione con COVID-19 - un primo caso riportato. Rheumatology (Oxford) 2021.[Epub ahead of print].
  3. Ahmed S, Zimba O, Gasparyan AY. COVID-19 e il corso clinico delle manifestazioni reumatiche. Clin Rheumatol. 2021: 1-9.
  4. Raghavan S, Gonakoti S, Asemota IR, Mba B. Un caso di flare di lupus eritematoso sistemico innescato da una grave malattia da coronavirus 2019. J Clin Rheumatol. 2020; 26: 234-36. DOI: https://doi.org/10.1097/RHU.0000000000001531
  5. Lokineni S, Mortezavi M. Miosite necrotizzante a insorgenza ritardata dopo infezione da COVID-19. Eur J Case Rep Int Med. 2021; 8: 002461.
  6. De Souza JM, Hoff LS, Shinjo SK. Terapie a impulsi di immunoglobulina umana per via endovenosa e/o metilprednisolone come possibile strategia treat-to-target nelle miopatie necrotizzanti immunomediate. Rheumatol Int. 2019; 39: 1201-12. DOI: https://doi.org/10.1007/s00296-019-04254-3
  7. De Souza, Miossi R, Shinjo SK. Miopatia necrotizzante associata ad anticorpo anti-signal recognition particle (anti-SRP). Clin Exp Rheumatol. 2017; 35: 766-71.

Metrics

Citations and online attention from Dimensions, Altmetric and PlumX.

PlumX Metrics

License

Copyright (c) 2022 the Author(s)

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.